Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983620 | 0.82 | ALDH1A1 (0.47) | MAPTSMN1; SMN2TDP1LMNAGPR35 | |
| SCHEMBL23751958 | 0.82 | TTR (0.61) | EGFRERN1TTRMAPTSMN1; SMN2 | |
| SCHEMBL17744307 | 0.82 | PDK1 (0.48) | EGFRTTRMAPTPOLBTDP1 | |
| SCHEMBL31276843 | 0.82 | TTR (0.47) | TTRMAPTPOLBTDP1MEN1 | |
| SCHEMBL6010796 | 0.81 | GPR35 (0.63) | TTRMAPTPOLBTDP1MEN1 | |
| SCHEMBL11070819 | 0.81 | GPR35 (0.69) | EGFRERN1TTRMAPTSMN1; SMN2 | |
| SCHEMBL8580120 | 0.81 | ERN1 (0.64) | EGFRERN1TTRMAPTSMN1; SMN2 | |
| SCHEMBL28825199 | 0.81 | ALDH1A1 (0.46) | MAPTSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL4018068 | 0.79 | KDM4E (0.47) | MAPTSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL20022338 | 0.79 | TTR (0.66) | EGFRERN1TTRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3020718-A1 | NOVEL PDE4 INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-7045516-B1 | Benzoxazole derivatives and drugs containing the same as the active ingredient | KOICHI SHUDO (JP) | 2006-05-16 | — | — | US | disclosed |
| EP-1134220-B1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | SHUDO KOICHI (JP) | 2004-08-18 | — | — | EP | disclosed |
| CN-1333771-A | Benzoxazole derivative and drug containing the same as active ingredient | MEIJI SEIKA KAISHA (JP) | 2002-01-30 | — | — | CN | disclosed |
| EP-1134220-A1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | FABP1, FABP5, FABP2 | EGFR 2367/4885ERN1 1845/4885TTR 351/4885 |
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | EGFR 4435/4885ERN1 1526/4885TTR 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.